LinqMed Inc.
- Biotech or pharma, therapeutic R&D
LinqMed Inc. is a Japan-based radiopharmaceutical start-up pioneering the development of “Visible Cancer Therapeutics” that combine diagnosis and therapy in a single platform using the copper radioisotope 64Cu.64Cu and can be used for both cancer diagnosis and treatment.Our lead compound, 64Cu-ATSM, selectively accumulates in hypoxic tumor cells, offering a novel approach to treating malignant brain tumors. Now in Phase III clinical trials, 64Cu-ATSM represents the world's first radiotherapeutic agent developed in Japan to reach this stage. LinqMed is seeking global pharmaceutical partners for licensing and overseas expansion, as well as collaborators for joint research involving 64Cu-labeled antibodies and peptides. Our mission is to link innovative science and medicine to deliver individualized cancer care that is both effective and visible in real time.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}